This is the case of a phase I trial for patients with prostate cancer, treated with adenovirus (CV706) in which the E1A, an adenoviral protein that inhibits cell cycle, was placed under promoter of prostate-specific antigen (PSA) [81]. Here, DHTKD1 is linked to Familial prostate cancer.